Compounds > 3,4-dihydroxybenzylamine

Page last updated: 2024-08-26

3,4-dihydroxybenzylamine and Melanoma

3,4-dihydroxybenzylamine has been researched along with Melanoma in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	7 (87.50)	18.7374
1990's	1 (12.50)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
FitzGerald, GB; Wick, MM	1
Wick, MM	4
FitzGerald, GB; Prezioso, JA; Wick, MM	1
Kable, EP; Parsons, PG	1
Prakash, NJ; Sjoerdsma, A; Sunkara, PS	1

Other Studies

8 other study(ies) available for 3,4-dihydroxybenzylamine and Melanoma

Article	Year
3,4-Dihydroxybenzylamine: an improved dopamine analog cytotoxic for melanoma cells in part through oxidation products inhibitory to dna polymerase. The Journal of investigative dermatology, 1983, Volume: 80, Issue:2 Topics: Animals; Biotransformation; Cattle; DNA Polymerase II; DNA Replication; Dopamine; Doxorubicin; Enzyme Activation; Melanoma; Mice; Monophenol Monooxygenase; Neoplasms, Experimental; Nucleic Acid Synthesis Inhibitors; Thymus Gland	1983
Levodopa and dopamine analogs as DNA polymerase inhibitors and antitumor agents in human melanoma. Cancer research, 1980, Volume: 40, Issue:5 Topics: Animals; Cell Membrane Permeability; Cells, Cultured; DNA, Neoplasm; Dopamine; Humans; Levodopa; Melanoma; Mice; Monophenol Monooxygenase; Neoplasms, Experimental; Nucleic Acid Synthesis Inhibitors; Quinones	1980
3,4-Dihydroxybenzylamine: a dopamine analog with enhanced antitumor activity against B16 melanoma. Journal of the National Cancer Institute, 1979, Volume: 63, Issue:6 Topics: Animals; Cells, Cultured; Dopamine; Melanoma; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Thymidine	1979
Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan. The Journal of investigative dermatology, 1992, Volume: 99, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Dopamine; Glutathione Peroxidase; Humans; Hydrogen Peroxide; Melanoma; Melanoma, Experimental; Melphalan; Methionine Sulfoximine; Mice; Tumor Cells, Cultured	1992
Levodopa/dopamine analogs as inhibitors of DNA synthesis in human melanoma cells. The Journal of investigative dermatology, 1989, Volume: 92, Issue:5 Suppl Topics: Animals; DNA; Dopamine; Dose-Response Relationship, Drug; Humans; Levodopa; Melanocytes; Melanoma; Mice; Skin Neoplasms	1989
Melanin synthesis and the action of L-dopa and 3,4-dihydroxybenzylamine in human melanoma cells. Cancer chemotherapy and pharmacology, 1989, Volume: 23, Issue:1 Topics: Cell Cycle; Cell Survival; DNA, Neoplasm; Dopamine; Humans; Levodopa; Melanins; Melanoma; Oxidation-Reduction; RNA, Neoplasm; Superoxide Dismutase; Tumor Cells, Cultured	1989
Inhibition of transformation by levodopa-carbidopa in lymphocytes derived from patients with melanoma. The Journal of investigative dermatology, 1987, Volume: 88, Issue:5 Topics: Carbidopa; Dopamine; Drug Combinations; Humans; Levodopa; Lymphocyte Activation; Melanoma; Osmolar Concentration; Phytohemagglutinins	1987
Potentiation by alpha-difluoromethylornithine of the activity of 3,4-dihydroxybenzylamine, a tyrosinase-dependent melanolytic agent, against B16 melanoma. Biochemical pharmacology, 1985, Jun-01, Volume: 34, Issue:11 Topics: Catechol Oxidase; Cells, Cultured; Dopamine; Drug Synergism; Eflornithine; Humans; Melanoma; Monophenol Monooxygenase; Ornithine; Ornithine Decarboxylase Inhibitors	1985